Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.9000 (1.37%) ($5.7500 - $5.9400) on Tue. Jul. 9, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.22% (three month average) | RSI | 77 | Latest Price | $5.9000(1.37%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.5% a day on average for past five trading days. | Weekly Trend | ADMS advances 4.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(10%) LQD(6%) SHY(6%) VCIT(6%) JETS(4%) | Factors Impacting ADMS price | ADMS will decline at least -1.61% in a week (0% probabilities). INDA(-8%) BNDX(-7%) XLE(-6%) USO(-6%) URA(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.61% (StdDev 3.22%) | Hourly BBV | 0 () | Intraday Trend | 2.3% | | | |
|
5 Day Moving Average | $5.92(-0.34%) | 10 Day Moving Average | $5.95(-0.84%) | 20 Day Moving Average | $5.49(7.47%) | To recent high | -12.3% | To recent low | 16.8% | Market Cap | $167m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |